[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"amenorrhea\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:amenorrhea":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,47,79,110,137,162,194],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":4,"leadSponsor":43,"locationsCount":46},"100171064","inherited-reproductive-disorders-100171064",false,"NCT01500447","Inherited Reproductive Disorders","The Molecular Basis of Inherited Reproductive Disorders","* INCLUSION CRITERIA:\n\nThe essential inclusion criteria include:\n\n1. failure to go through a normal, age-appropriate, spontaneous puberty and low sex steroid levels in the setting of low\u002Fnormal gonadotropins (due to substantial variability among patient presentations, this will be based on the clinical judgement of the Investigator), or\n2. abnormally early development of puberty, or\n3. normal puberty with subsequent development of low gonadotropin levels, or\n4. individuals with features indicating an increased risk of hypogonadotropic hypogonadism.\n5. Family members: both affected and unaffected family members are strongly encouraged to participate.\n\nEXCLUSION CRITERIA:\n\nSince hypogonadotropic hypogonadism is a rare condition, this protocol remains open to enrollment so that we may study all subjects that are both qualified and interested in participating.\n\nBecause HH represents a spectrum, where associated clinical findings may provide phenotypic clues to the assessment of inheritability and underlying physiology, exclusion criteria are very limited:\n\n* Patients who have additional pituitary deficiencies, effectively ruling out isolated GnRH deficiency, whether these deficiencies are congenital or acquired (e.g. secondary to malignancy, infection, or irradiation).\n* Patients who are taking medications known to affect GnRH secretion, such as corticosteroids or continuous opiate administration (or were taking them at the time of diagnosis).","ALL","6 Weeks","120 Years",{"count":20,"type":21},850,"ESTIMATED","OBSERVATIONAL","Background:\n\n\\- During puberty, children begin to develop into adults. Problems with the hormones released during puberty can affect the reproductive system. Some people have low hormone levels that severely delay or prevent puberty. Others start puberty abnormally early. Other people may have a normal puberty but develop reproductive disorders later in life. Researchers want to study people with reproductive disorders to learn more about how these disorders may be inherited.\n\nObjectives:\n\n\\- To learn how reproductive system disorders may be inherited.\n\nEligibility:\n\n* People with one of the following problems:\n* Abnormally early puberty\n* Abnormally late or no puberty\n* Normal puberty with hormonal problems that develop later in life\n* People who have not yet had puberty but have symptoms that indicate low hormone levels.\n\nDesign:\n\n* Participants will provide a blood sample for testing. They will complete a questionnaire about their symptoms. They will also have a scratch-and-sniff test to study any problems with their ability to smell.\n* Participant medical records will be reviewed. Participants will also provide a family medical history.\n* Family members of those in the study may be invited to participate.\n* Treatment will not be provided as part of this study.",[25,26,27,28],"Genetic Disorder","Infertility","Hypogonadism","Amenorrhea",[30,31,32,33,34,35],"Hypogonadotropic Hypogonadism","Kallmann Syndrome","Delayed Puberty","Hypothalamic Amenorrhea","Precocious Puberty","Natural History","RECRUITING","2026-06-23",{"date":39,"type":40},"2026-06-24","ACTUAL",{"date":42,"type":40},"2012-04-25",{"name":44,"class":45},"National Institute of Environmental Health Sciences (NIEHS)","NIH",2,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":55,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100638662","effects-of-resistance-training-on-women-with-functional-hypothalamic-amenorrhea-100638662","NCT07612735","Effects of Resistance Training on Women With Functional Hypothalamic Amenorrhea","Impact of Strength Training on Mental Health and Physical Fitness in Women With Functional Hypothalamic Amenorrhea","Inclusion Criteria:\n\n* General Profile: Active women aged 18 to 35 years.\n* FHA Group: Clinical diagnosis of Functional Hypothalamic Amenorrhea, defined as the absence of menstruation for at least three consecutive months not attributable to other endocrine disorders.\n* Control Group (EU): Eumenorrheic women with regular ovulatory cycles lasting between 24 and 35 days during the previous six months.\n* Commitment: Agreement to participate in a supervised 8-week resistance training program and provision of medical documentation confirming menstrual status.\n\nExclusion Criteria:\n\n* Hormonal Status: Current use of any hormonal contraceptives.\n* Medical Conditions: Diagnosed endocrine disorders such as Polycystic Ovary Syndrome (PCOS), hyperandrogenism, or thyroid dysfunction.\n\nPregnancy: Current pregnancy.\n\n* Physical Activity History: Engagement in any structured resistance training program during the three months prior to the start of the intervention.\n* General Health: Any medical condition that could interfere with the study protocol or the ability to perform physical exercise.",true,"FEMALE","18 Years",{"count":58,"type":21},28,"INTERVENTIONAL",[61],"NA","Functional hypothalamic amenorrhea (FHA) is a condition where women lose their menstrual periods, typically due to a combination of stress and insufficient calorie intake to fuel their daily physical activity (low energy availability). Standard medical advice often requires these women to completely stop exercising to recover their energy balance and hormones. However, this \"complete rest\" approach can cause severe anxiety for active individuals and removes the necessary mechanical loading that keeps bones strong.\n\nThis study evaluates the safety and effectiveness of an 8-week supervised resistance training (weightlifting) program as a realistic alternative treatment for active women with FHA. The researchers compare a group of women experiencing FHA to a control group of women with regular menstrual cycles. Over the 8 weeks, participants complete three moderate-intensity, full-body weightlifting sessions per week.\n\nThe primary goal is to determine if women with FHA can successfully recover their menstrual cycles while continuing to lift weights. Additionally, the study monitors changes in muscle strength, jumping performance, body composition, resting heart rate, and psychological well-being. Ultimately, this study aims to provide healthcare providers and coaches with evidence-based strategies that allow female athletes to safely maintain their athletic identity and physical health during recovery.",[28,64,65,66],"Functional Hypothalamic Amenorrhea (FHA)","Low Energy Availability","Relative Energy Deficiency in Sport","NOT_YET_RECRUITING","2026-05-22",{"date":70,"type":40},"2026-05-29",{"date":72,"type":21},"2026-05-15",{"date":74,"type":21},"2026-07-25",{"name":76,"class":77},"Catholic University of Murcia","OTHER",1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":55,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":59,"phases":90,"briefSummary":91,"conditions":92,"keywords":95,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":109},"100577582","treatment-of-menstrual-cycle-alterations-in-adolescents-100577582","NCT06800170","Treatment of Menstrual Cycle Alterations in Adolescents","HP-phD_Adolesc","Inclusion Criteria:\n\n* adolescent women aged 14-19 years old, with at least 3 years passed after menarche, and oligomenorrhea or amenorrhea\n\nExclusion Criteria:\n\n* Primary amenorrhea.\n* Hyperandrogenism due to other factors (i.e. adrenal hyperplasia or Cushing syndrome).\n* Hyperprolactinemia or overt hypothyroidism (TSH ≥4).\n* Other hormonal alterations.\n* Ongoing hormonal therapies, including OCPs, six months before enrollment.\n* Ongoing pharmacological therapies.\n* Ongoing use of myo-Inositol supplement or other source of myo-Inositol, or Dioscorea villosa, six months before enrollment.","14 Years","19 Years",{"count":89,"type":21},20,[61],"the aim of the present study is intended to evaluate how treatment with Myo-Inositol and Dioscorea Villosa can help improve menstrual cycle irregularities in adolescents, both with and without PCOS.",[28,93,94],"Oligomenorrhea","PCOS (Polycystic Ovary Syndrome)",[96,97,98],"myo-Inositol","Dioscorea Villosa","adolescents","2026-01-05",{"date":101,"type":40},"2026-01-06",{"date":103,"type":40},"2025-06-01",{"date":105,"type":21},"2026-12",{"name":107,"class":108},"Lo.Li.Pharma s.r.l","INDUSTRY",3,{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":16,"minAge":117,"maxAge":118,"enrollmentInfo":119,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":121,"conditions":122,"keywords":125,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":78},"100537667","observation-of-environment-and-reproductive-endocrine-effects-100537667","NCT06280807","Observation of Environment and Reproductive-Endocrine Effects","OBServation of Environment and ReproductiVe Endocrine Effects Study (OBSERVE Study)","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Male or female, referring to sex assigned at birth (cis gender)\n2. Age \\> 8 years and weight \\>= 12 kg\n3. A diagnosis of hypogonadism, infertility or other reproductive dysfunction\n\n   Some specific diagnoses (as defined in standard guidelines) will include:\n   * Male or female hypogonadism\n\n     * Obesity\u002Fmetabolic syndrome related to hypogonadism.\n     * Other reproductive dysfunction (e.g., secondary to endocrine dysfunction, thyroid disorders, Cushing syndrome, pharmacotherapy, etc.)\n     * Premature Ovarian Insufficiency\n     * Isolated hypogonadotropic hypogonadism\n   * Polycystic Ovarian Syndrome\n   * Delayed Puberty\n   * Precocious puberty\n   * Perimenopause and post-menopausal states\n   * Androgen Excess States (Nonclassic Congenital Adrenal Hyperplasia, Extreme hyperinsulism, Idiopathic etc.)\n\n   or\n\n   -Exhibiting signs of a diagnosis of hypogonadism, e.g., Bosma arrhinia microphthalmia syndrome (BAMS)\n4. Ability of participant, legal guardian, or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. A diagnosis of a serious medical disorder such as malignancy or heart disease will be grounds for exclusion at the discretion of the PI or AI.\n2. Inability to follow up with the research study and\u002For perform study procedures, at the discretion of the PI or AI.\n3. Pregnant participants, less than 18 years of age, for their safety, since there is not a trained doctor on the study to give proper medical care to pregnant individuals less than 18 years of age.\n\nIndividuals who do not meet the criteria for participation in this study (screen failure) because of an acute, reversible or transient medical reason may be rescreened upon reversal, improvement or stabilization of their clinical status. Participants who develop an acute, reversible or transient medical condition during the study may return upon reversal, improvement or stabilization of their clinical status.","8 Years","99 Years",{"count":120,"type":21},300,"Background:\n\nEndocrine disorders occur when the glands that make hormones do not work properly. Hormones levels that are too high or too low can cause problems such as late or early puberty, irregular periods, and infertility. Environmental factors - including pollution; chemical exposure at home and work; foods; medicines; and sleep habits - may cause problems with the endocrine and reproductive systems.\n\nObjective:\n\nTo learn how environmental factors may affect the endocrine and reproductive systems.\n\nEligibility:\n\nMales or females, referring to sex assigned at birth, aged 8 years and older; they must have hypogonadism, infertility, or other reproductive disorders.\n\nDesign:\n\nAdult participants will have 4 to 5 visits in 5 years. Children may have up to 12 visits; they may remain in the study up to the age of 23. Most visits will be less than 3 hours.\n\nParticipants will be screened. They will have a physical exam. They will have blood and urine tests. They will complete questionnaires; they will answer questions about their diet, health, and other topics. Some may be referred for additional tests, such as imaging scans and semen analysis.\n\nSpecific tests conducted during study visits will vary, depending on the participant s diagnosis. In addition to repeated blood and urine tests, these may include:\n\nBody composition measure: Participants will sit in a pod-shaped machine for about 6 minutes. The machines measures the air inside the capsule to record body fat and breathing volume.\n\nResting energy expenditure test: Participants will lie down with a clear dome placed over their head. They will breathe quietly for 30 minutes. This test measures the number of calories their body burns at rest.\n\n...",[27,123,34,124,28],"Hypergonadism","Late Puberty",[126,127,128],"Endocrine","Reproductive Disorders","Hypothalamic-Pituitary-Gonadal Endocrine Axis","2025-12-20",{"date":131,"type":40},"2025-12-23",{"date":133,"type":40},"2024-07-01",{"date":135,"type":21},"2039-03-31",{"name":44,"class":45},{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":55,"minAge":144,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":148,"conditions":149,"keywords":150,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":78},"100594133","retrospective-observational-evaluation-of-the-bone-mineral-density-outcome-in-young-women-with-amenorrhea-100594133","NCT07015476","Retrospective Observational Evaluation of the Bone Mineral Density Outcome in Young Women With Amenorrhea","Retrospective Observational Evaluation of the Bone Mineral Density Outcome of Different Oestrogen Therapy Regimens in Young Women With Amenorrhea","Inclusion criteria:\n\n* Patients who have presented themselves to the O.U. of Gynecology and Human Reproduction Pathophysiology in the period from 2011 to 2020 with amenorrhea over 6 months, and aged between 15 and 39 years at the time of the visit.\n* Patients who have reached the age of 18 at the time of surgery.\n* Patients for whom informed consent has been obtained.\n\nExclusion criteria: No exclusion criteria are provided.","15 Years","39 Years",{"count":147,"type":21},180,"The study aims to evaluate the outcomes of different estrogen therapy regimens in patients with amenorrhea who face prolonged periods of hypoestrogenism.\n\nThe primary objective is to compare the outcomes on bone mass of different therapeutic regimens and identify more favorable. For this purpose, densitometry parameters such as BMD, T-score and Z-score at the level of the lumbar spine, femur and entire skeleton will be considered, comparing a bone densitometry (DXA technique, Dual X-ray Absorptiometry) Baseline with one carried out after at least one year of therapy. The secondary objective of the study is to assess other systemic\u002Fmetabolic implications of the different therapies.",[28],[28,151,152],"Bone Mass","Estrogen Therapy","2025-06-03",{"date":155,"type":40},"2025-06-11",{"date":157,"type":40},"2020-11-09",{"date":159,"type":21},"2026-11",{"name":161,"class":77},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":54,"sex":55,"minAge":170,"maxAge":171,"enrollmentInfo":172,"targetDuration":4,"studyType":59,"phases":174,"briefSummary":177,"conditions":178,"keywords":182,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":78},"100356129","phase-2-autologous-prp-intra-ovarian-infusion-to-restore-ovarian-function-in-menopausal-women-100356129","NCT03916978","Autologous PRP Intra Ovarian Infusion to Restore Ovarian Function in Menopausal Women","Investigating Reactivation of Ovarian Function Following Autologous PRP Intra-ovarian Infusion in Menopausal Women","PRP","Inclusion Criteria:\n\n* Age between 45-55 years old\n* Amenorrhea for at least 12 months\n* Discontinuation of any complementary\u002Fadjuvant treatment including hormone replacement, acupuncture, and botanotherapy, for at least three months prior to recruitment.\n* Willing to comply with study requirements\n\nExclusion Criteria:\n\n* Any pathological disorder related to reproductive system anatomy\n* Previous POI diagnosis\n* Abnormal karyotype\n* Endometriosis\n* Adenomyosis\n* Fibroids and adhesions\n* Infections in reproductive system\n* Current or previous diagnosis of reproductive system cancer\n* History of familiar cancer in reproductive system\n* Severe male factor infertility\n* Prior referral for PGT\n* Ovarian inaccessibility\n* Endocrinological disorders (Hypothalamus-Pituitary disorders, thyroid dysfunction, diabetes mellitus, metabolic syndrome)\n* BMI\\>30 kg\u002Fm2 or BMI\\\u003C18.5 kg\u002Fm2\n* Systematic autoimmune disorders","45 Years","55 Years",{"count":173,"type":21},100,[175,176],"PHASE2","PHASE3","Autologous PRP intra ovarian infusion may restore ovarian function, may promote folliculogenesis and may improve hormonal profile of women in menopause.",[179,180,181,28],"Infertility, Female","Anovulatory Infertility","Menopause",[183,184],"Ovarian rejuvenation","Ovarian reactivation; ovulation","2024-12-20",{"date":187,"type":40},"2024-12-27",{"date":189,"type":40},"2019-05-21",{"date":191,"type":21},"2026-07-30",{"name":193,"class":77},"Genesis Athens Clinic",{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":200,"eligibilityCriteria":201,"healthyVolunteers":54,"sex":55,"minAge":202,"maxAge":203,"enrollmentInfo":204,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":206,"conditions":207,"keywords":209,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":109},"100395092","ovarian-morphology-in-girls-100395092","NCT04424576","Ovarian Morphology in Girls","Trajectory of Ovarian Morphology During the Adolescent Reproductive Transition","OMG","Inclusion Criteria:\n\n* Female adolescents aged 9 to 17 years\n* Menarche within 11 months of the enrollment visit\n* University of Rochester site only: Family history of PCOS (i.e., mother or aunt)\n\nExclusion Criteria:\n\n* Current or recent use of medications or supplements known or suspected to interfere with reproductive or metabolic function in the past 2 months (e.g., contraceptives, metformin, steroids, anti-seizure medications)\n* Untreated and\u002For unstable medical or mental health condition known or suspected to interfere with reproductive or metabolic function\n* Currently pregnant or breast feeding\n* History of ovarian surgery\n* Presence of significant acute or chronic illness which may interfere with study participation","9 Years","17 Years",{"count":205,"type":21},60,"Establishment of regular menstrual cycles is a key component of reproductive maturation and a recognized vital sign for health and well-being. Irregular menstrual cycles are especially common for the first 2-3 years after an adolescent's first menstrual period (i.e., menarche), which delays the identification and diagnosis of early reproductive disturbances such as polycystic ovary syndrome (PCOS). The purpose of this research study is to determine whether the ovary can serve as a reliable predictor of normal or abnormal development by following the trajectory of ovarian morphology in conjunction with menstrual cyclicity using 3D transabdominal ultrasound imaging in a prospective cohort study of adolescents. A secondary objective is to identify potential environmental factors such as diet and the gut microbiome which influence the trajectory towards normal or abnormal reproductive development.",[28,93,208],"Puberty",[210,211,212,213,214],"Ovary","Transabdominal Ultrasound","Menarche","Periods","Microbiome","2024-08-08",{"date":217,"type":40},"2024-08-12",{"date":219,"type":40},"2020-01-31",{"date":221,"type":21},"2025-03-31",{"name":223,"class":77},"Cornell University"]